Prognostic significance of heat shock protein 90AA1 (HSP90α) in invasive breast cancer

Aims The mechanisms that drive breast cancer (BC) progression and poor outcome are not fully understood. The human heat shock protein 90 alpha family class A member 1 (HSP90α) encoded by the HSP90ΑA1 gene has a vital role in cellular responses to stress and is implicated in the development and progression of many cancers. The current study aims to explore the clinical and prognostic importance of HSP90α in BC. Methods The Molecular Taxonomy of Breast Cancer International Consortium (n=1980); The Cancer Genome Atlas (n=1097) and the Breast Cancer Gene-Expression Miner (Bc-GenExMiner) BC datasets (n=5056) were used to evaluate HSP90ΑA1 mRNA expression. HSP90α protein expression was further assessed using immunohistochemistry in a large (n=911) well-characterised BC series. The association between mRNA and protein expressions with other clinicopathological parameters and outcome was analysed. Results High expression of HSP90ΑA1 both at the mRNA and protein levels was significantly associated with characteristics of BC poor prognosis, including high grade, lymphovascular invasion, poor Nottingham Prognostic Index and positive expression of p53 and PIK3CA. Outcome analysis revealed that high HSP90α protein expression is an independent predictor of shorter BC-specific survival. Conclusion HSP90α can be used as a potential prognostic marker in BC. Further mechanistic studies are warranted to determine the underlying molecular mechanisms mediated by HSP90α in BC.

[1]  M. Żylicz,et al.  Heat shock proteins create a signature to predict the clinical outcome in breast cancer , 2019, Scientific Reports.

[2]  F. Cecconi,et al.  Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications , 2019, Cell Death & Differentiation.

[3]  Daoying Wang,et al.  Interaction of Hsp90AA1 with phospholipids stabilizes membranes under stress conditions. , 2019, Biochimica et biophysica acta. Biomembranes.

[4]  Rensheng Wang,et al.  Prognostic value of the mRNA expression of members of the HSP90 family in non-small cell lung cancer , 2019, Experimental and therapeutic medicine.

[5]  Lin Lin,et al.  Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer , 2019, Journal of Cancer.

[6]  Ping Yang,et al.  KCNQ1OT1 facilitates progression of non‐small‐cell lung carcinoma via modulating miRNA‐27b‐3p/HSP90AA1 axis , 2018, Journal of cellular physiology.

[7]  Xin Xiao,et al.  HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma , 2018, Journal of experimental & clinical cancer research : CR.

[8]  E. Rakha,et al.  Breast cancer intratumour heterogeneity: current status and clinical implications , 2018, Histopathology.

[9]  Lequn Li,et al.  Expression of HSP90AA1/HSPA8 in hepatocellular carcinoma patients with depression , 2018, OncoTargets and therapy.

[10]  M. Watanabe,et al.  The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment , 2018, International reviews of immunology.

[11]  J. Błasiak,et al.  The Long Noncoding RNA HOTAIR in Breast Cancer: Does Autophagy Play a Role? , 2017, International journal of molecular sciences.

[12]  E. Cesarman,et al.  Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma , 2017, Molecular Cancer Therapeutics.

[13]  Miki Ohira,et al.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes , 2016, Journal of Human Genetics.

[14]  Soon-Sun Hong,et al.  HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer , 2016, Oncotarget.

[15]  Wei Zhu,et al.  Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials. , 2016, Molecular and clinical oncology.

[16]  K. Arihiro,et al.  Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. , 2016, Japanese journal of clinical oncology.

[17]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[18]  Wei Li,et al.  Keratinocyte-Secreted Heat Shock Protein-90alpha: Leading Wound Reepithelialization and Closure. , 2016, Advances in wound care.

[19]  K. Sabapathy.  The Contrived Mutant p53 Oncogene – Beyond Loss of Functions , 2015, Front. Oncol..

[20]  L. Neckers,et al.  Regulation and function of the human HSP90AA1 gene. , 2015, Gene.

[21]  T. Soussi,et al.  TP53: an oncogene in disguise , 2015, Cell Death and Differentiation.

[22]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[23]  M. Chircop,et al.  Cellular Stress Responses in Cancer and Cancer Therapy , 2014, Front. Oncol..

[24]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[25]  I. Ellis,et al.  Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study , 2014, Breast Cancer Research and Treatment.

[26]  G. Ball,et al.  Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer , 2014, British Journal of Cancer.

[27]  I. Ellis,et al.  Characteristics of basal cytokeratin expression in breast cancer , 2013, Breast Cancer Research and Treatment.

[28]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[29]  Chad J Creighton,et al.  The molecular profile of luminal B breast cancer , 2012, Biologics : targets & therapy.

[30]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[31]  Moyez Dharsee,et al.  Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival , 2012, PloS one.

[32]  M. Campone,et al.  bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer , 2012, Breast Cancer Research and Treatment.

[33]  H. Dyson,et al.  Dynamic Interaction of Hsp90 with Its Client Protein p53. , 2011, Journal of molecular biology.

[34]  I. Ellis,et al.  Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer , 2012, Breast Cancer Research.

[35]  I. Ellis,et al.  Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer , 2011, Breast Cancer Research and Treatment.

[36]  Andrew R. Green,et al.  MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.

[37]  S. Calderwood.  Heat shock proteins in breast cancer progression–A suitable case for treatment? , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[38]  I. Ellis,et al.  PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis , 2010, Breast Cancer Research and Treatment.

[39]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[40]  Yuval Kluger,et al.  High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.

[41]  I. Ellis,et al.  The p53 positive Bcl‐2 negative phenotype is an independent marker of prognosis in breast cancer , 2007, International journal of cancer.

[42]  G. Kroemer,et al.  Heat Shock Proteins 27 and 70: Anti-Apoptotic Proteins with Tumorigenic Properties , 2006, Cell cycle.

[43]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[44]  Stuart K. Calderwood,et al.  Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications , 2005, Cell stress & chaperones.

[45]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[46]  T. Isobe,et al.  IC101 Induces Apoptosis by Akt Dephosphorylation via an Inhibition of Heat Shock Protein 90-ATP Binding Activity Accompanied by Preventing the Interaction with Akt in L1210 Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[47]  L. Neckers,et al.  Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness , 2004, Nature Cell Biology.

[48]  Jiandong Chen,et al.  Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization* , 2001, The Journal of Biological Chemistry.

[49]  K. Bhalla,et al.  Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. , 2001, Cancer research.

[50]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Srinivasula,et al.  Negative regulation of cytochrome c‐mediated oligomerization of Apaf‐1 and activation of procaspase‐9 by heat shock protein 90 , 2000, The EMBO journal.

[52]  D. Whitley,et al.  Heat shock proteins: a review of the molecular chaperones. , 1999, Journal of vascular surgery.

[53]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[54]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.